FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2084-2086 November 15, 2007 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Saag, K. G. PubMed Citation

Glucocorticoids are widely used because of their important and efficacious immunosuppressive and antiinflammatory properties. However, glucocorticoid-induced osteoporosis, a major adverse event, is a common clinical problem. The risk of osteoporosis with glucocorticoid therapy remains unclear, but the disease has been reported to occur in up to 50% of patients who require long-term therapy. Fractures can occur rapidly, with a predilection for sites that are rich in trabecular bone, such as the spine and ribs.

There are few prospective epidemiologic data regarding fractures and their association with glucocorticoid-induced bone loss, but a large, retrospective cohort study of patients receiving glucocorticoids who . . . [Full Text of this Article]

Source Information

From the Kolling Institute, University of Sydney, Sydney.

Related Letters:

Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Rossi C. M., Di Comite G., Babb R. R., Nori U. S., Agarwal A. K., Rovin B. H., Saag K. G., Shane E., Marcus R.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1302-1304, Mar 20, 2008. Correspondence

This article has been cited by other articles:

• Rossi, C. M., Di Comite, G., Babb, R. R., Nori, U. S., Agarwal, A. K., Rovin, B. H., Saag, K. G., Shane, E., Marcus, R. (2008). Teriparatide or alendronate in glucocorticoid-induced osteoporosis.. NEJM 358: 1302-1303 [Full Text]